Introduction
Vascular Endothelial Growth Factor (VEGF) is involved in endothelial cell proliferation, microvascular permeability, vasodilatation and angiogenesis. Angiogenesis, the sprouting of new capillaries from existing vasculature, is necessary for vascular development, wound healing, organ regeneration, and has been involved in disease states such as diabetic retinopathy, rheumatoid arthritis and tumor growth (Carmeliet, 2000; Ferrara and Davis, 1997; Risau, 1997) . VEGF binds to two speci®c tyrosine kinase receptors expressed only on endothelial cells, Flt-1 (Fms like tyrosine kinase) and Flk/KDR (Kinase insert domain containing receptor). Both receptors are structurally related to the PDGF (Platelet Derived Growth Factor) receptor family (Neufeld et al., 1999) . Knock-out studies have shown that these receptors have dierent biological functions. Indeed, in Flk null mice, endothelial and hematopoietic cell development is impaired. In Flt-1 knock-out mice, there is an apparent overgrowth of endothelial cells, and blood vessels are disorganized (Fong et al., 1995; Shalaby et al., 1995) . These results and other studies performed by activating separately only one receptor suggest that KDR is involved in endothelial cell proliferation and survival, while Flt-1 seems to be required for chemotaxis and procoagulant activity. Although both receptors are capable of autophosphorylation in vitro (Waltenberger et al., 1994) , only KDR autophosphorylates in vivo. The deletion of the tyrosine kinase domain of Flt-1 does not impair blood vessel formation in homozygous mice, suggesting that the kinase domain of Flt-1 is not required for its action on angiogenesis (Hiratsuka et al., 1998) .
A series of steps in the VEGF signaling pathway have been elucidated. Activation of VEGF receptors promotes tyrosine phosphorylation of several proteins, and recruitment of SH2-containing molecules (Waltenberger et al., 1994) . Stimulation of KDR leads to PI-3-kinase and PKB activation (Gerber et al., 1998; Wu et al., 2000) , to MAP kinase activation through PLCg and PKC-dependent pathway (Takahashi et al., 1999) , to nitric oxide synthesis and to FAK tyrosine phosphorylation (Abedi and Zachary, 1997; Shen et al., 1999) . However, many players in VEGF signaling have still to be discovered. Tyrosine kinase receptors control signaling pathways through association of SH2 containing proteins and tyrosine phosphorylated proteins.
Grb10 protein contains several interaction motifs, such as a N-terminal proline-rich sequence, a central PH (Pleckstrin homology) domain, a BPS domain (Between PH and SH2) and a C-terminal SH2 domain (Frantz et al., 1997; He et al., 1998; Ooi et al., 1995) . Although Grb10 interacts with tyrosine kinase receptors such as PDGF, EGF, insulin and IGF-I receptors, its function as an adapter molecule remains to be discovered (He et al., 1998; Stein et al., 1996) . Indeed, Grb10 binds to signaling molecules such as Raf1, MEK1, BCR-Abl, Jak2, NEDD4 (Nantel et al., 1998; Bai et al., 1998; Moutoussamy et al., 1998; Morrione et al., 1999) , but the consequences of these associations have not been elucidated. The role of Grb10 in cellular signaling is controversial. According to some authors, microinjection of the Grb10 SH2 domain decreases insulin-and IGF-I-mediated mitogenesis (Morrione et al., 1997) , while in other reports, Grb10 has a positive role in PDGF, IGF-I and insulin-induced mitogenesis (Wang et al., 1999) .
In this study, we show that Grb10 is tyrosine phosphorylated in response to VEGF in HUVEC and in 293 cells expressing KDR. Moreover, VEGF increases Grb10 mRNA in HUVEC. In 293 cells and in HUVEC, overexpression of Grb10 induces an increase in the amount and in the tyrosine phosphorylation of KDR, coupled to an increase in the VEGFinduced MAP kinase activity. We show that Grb10 interacts directly with VEGF receptor KDR, and that the SH2 domain of Grb10 mediates this association. Since VEGF stimulates the expression of Grb10 mRNA, and Grb10 increases KDR molecules, we would like to suggest that a positive feed-back loop could exist.
Results

KDR interacts with Grb10 SH2 domain
Although Grb10 binds to several tyrosine kinase receptors, its biological role remains unknown. To elucidate the function of Grb10, we investigated its implication in VEGF signaling.
VEGF binds to two tyrosine kinase receptors, Flt-1 and KDR. Since it has been shown that only KDR autophosphorylates in endothelial cells, we determined whether KDR interacts with Grb10 using the yeast two hybrid system. KDR cDNA corresponding to the cytoplasmic domain of the receptor was subcloned in frame with the binding domain of LexA. Grb10 cDNA was subcloned in frame with the activation domain of Gal-4. Yeasts were co-transformed by the two hybrids, and the association between the proteins was measured by the transactivation of a reporter gene, LacZ. Results in Figure 1a , show that pLex-KDR interacts with pAct-Grb10 as compared to a negative control, Raf. This interaction is dependent on the tyrosine kinase activity of the receptor, since the generation of a kinase-dead mutant (KD) of KDR by replacement of lysine 868 by alanine, abolishes the interaction of KDR with Grb10 in the yeast two hybrid system.
To localize the binding site on Grb10, we generated several mutants of pACT-Grb10 ( Figure 1b) . As represented, Grb10 possesses a proline-rich region, a PH domain, a BPS region and a SH2 domain. All the deletion mutants of Grb10 were tested for their abilities to bind to pLex-KDR (Figure 1c) . The SH2 domain of Grb10 binds to KDR, but not the N-terminal region (NT) nor the BPS domain. Grb10R 462 K possesses a non functional SH2 domain due to the replacement of the conserved arginine 462 by a lysine. This mutant is unable to associate with KDR in yeast two hybrid. All the results show that Grb10 binds to KDR only through its SH2 domain. In each condition, the amount of expressed proteins was identical as revealed by Western blot (data not shown). We conclude that association of Grb10 to KDR is dependent on the tyrosine kinase activity of the receptor, and requires a functional SH2 domain of Grb10.
Grb10 is tyrosine phosphorylated in response to VEGF
We studied whether Grb10 is tyrosine phosphorylated in response to VEGF. Human endothelial cells (HUVEC) were stimulated with VEGF and tyrosine phosphorylation of endogenous Grb10 was assessed after immunoprecipitation with an antibody to Grb10. As shown in Figure 2a , VEGF treatment induces a three-fold increase in Grb10 tyrosine phosphorylation.
To study the mechanism of this phosphorylation, we expressed epitope-tagged Grb10-HA and KDR-Myc in 293 cells (that lack endogenous VEGF receptors). Cells were stimulated with VEGF, and Grb10-HA was immunoprecipitated with an antibody to the HA epitope followed by an antiphosphotyrosine immunoblot. As shown in Figure 2b , VEGF-induced activation of KDR stimulates Grb10 tyrosine phosphorylation. Grb10 phosphorylation is abolished when a SH2 domain de®cient mutant of Grb10 is expressed (Grb10 R 462 K) (Figure 2c ).
Src is known to phosphorylate Grb10 on tyrosine (Langlais et al., 2000) . Moreover, Src kinases are involved in VEGF signaling pathway (Eliceiri et al., 1999) . To study whether phosphorylation of Grb10 in response to VEGF could be due to Src, we treated HUVEC with the Src inhibitor, PP2 prior to VEGF stimulation. We observed that PP2 treatment of HUVEC did not aect the VEGF-induced tyrosine phosphorylation of KDR (Figure 3a) . Grb10 was immunoprecipitated and analysed by antiphosphotyrosine immunoblot (Figure 3b ). PP2 treatment of HUVEC induces a 40% decrease in the VEGF induced tyrosine phosphorylation of Grb10. However, the tyrosine phosphorylation of Grb10 is not totally blocked suggesting that both Src and KDR are involved in the tyrosine phosphorylation of Grb10 after VEGF stimulation. In conclusion, Grb10 is tyrosine phosphorylated in response to VEGF. This phosphorylation seems to be due to both an action of KDR and Src.
Grb10 mRNA is increased by VEGF
Since Grb10 seems to be involved in VEGF signaling, we investigated whether VEGF could modulate Grb10 expression. Endothelial cells (HUVEC) were treated with VEGF for 2, 4 and 6 h, RNA were extracted, and Northern blot analysis was performed using a KDR or a Grb10 cDNA speci®c probe ( Figure 4 ). We observed that VEGF induces a threefold increase in Grb10 mRNA in HUVEC.
Ectopic expression of Grb10 increases KDR protein and its tyrosine phosphorylation
Since Grb10 expression is increased in response to VEGF, we studied its role on VEGF signaling pathway. We transfected Grb10 in 293 cells expressing KDR. Cells were stimulated with VEGF and whole cell lysate was analysed by an immunoblot using antibody to phosphotyrosine ( Figure 5 , left panel). VEGF treatment induced tyrosine phosphorylation of KDRMyc (twofold increase). When Grb10-HA was expressed, two tyrosine phosphorylated proteins appeared, Grb10 and KDR. As already shown in Figure 2 , tyrosine phosphorylation of Grb10 is increased after VEGF stimulation. Moreover, after Grb10 expression, KDR is phosphorylated in absence of VEGF treatment, and its tyrosine phosphorylation is increased (twofold) by VEGF. To verify KDR expression level, a Western blot with antibody to Myc was performed. As observed in Figure 5 (right panel), expression of Grb10 increases the amount of KDR (®vefold). The same result was observed after immunoprecipitation of KDR-Myc (data not shown). An immunoblot using antibodies to Shc shows that equivalent amount of proteins have been loaded on the gel.
Since we have observed that Grb10 expression leads to an increase in the basal tyrosine phosphorylation of KDR, we investigated whether this basal phosphorylation was due to KDR itself. To this end, we generated a kinase-dead mutant of KDR (KDR KD ) by mutation of the ATP binding site (K868A). 293 cells were transfected with KDR or KDR KD in absence or in presence of Grb10, stimulated or not with VEGF, and whole cell lysates were analysed by immunoblots using antibodies to phosphotyrosine, to Myc, to HA or to Shc ( Figure 6 ). We observed that VEGF induces tyrosine phosphorylation of KDR (lane 2 compared (passage 2) were treated with 20 ng/ml VEGF for 10 min. Cell extracts were subjected to immunoprecipitation with antibody to Grb10. Proteins were revealed by a blot with antibodies to phosphotyrosine. (b) 293 were transfected with pcDNA3 (Mock) or with pcDNA3-KDR-Myc without or with pcDNA3-Grb10-HA. Cells were stimulated with 50 ng/ml VEGF for 10 min and cell extracts were subjected to immunoprecipitation with antibody to HA (12CA5). Proteins were revealed by a Western blot with antibodies to phosphotyrosine and to HA. (c) 293 were transfected with pcDNA3-KDR-Myc with pcDNA3-Grb10-HA or pcDNA-Grb10R 462 K-HA. Cells were stimulated with 50 ng/ml VEGF for 10 min and cell extracts were subjected to immunoprecipitation with antibody to HA (12CA5). Proteins were revealed by a blot with antibodies to phosphotyrosine and to HA Figure 3 VEGF-induced tyrosine phosphorylation of Grb10 is mediated by Src. HUVEC were treated with 2 mM PP2 for 30 min prior to VEGF stimulation (50 ng/ml for 5 min). (a) Whole cell lysates were analysed by a blot with antibodies to phosphotyrosine. (b) HUVEC cell lysates were subjected to immunoprecipitation using antibodies to Grb10, and analysed by Western blot with antibodies to phosphotyrosine. Western blots were revealed on Storm 840 (Molecular Dynamics) to lane 1), and that Grb10 expression induces an increase in the tyrosine phosphorylation and the amount of KDR (lanes 3, 4 compared to lanes 1, 2). As expected VEGF treatment did not stimulate KDR KD tyrosine phosphorylation (lane 6 compared to lane 5). Although Grb10 expression did not induce any detectable tyrosine phosphorylation of KDR KD , it induces an increase in the amount of KDR KD (lanes 7, Figure 4 VEGF induces an increase in Grb10 mRNA in HUVEC. HUVEC (passage 2) were stimulated for 2, 4 and 6 h with VEGF (20 ng/ml) at 378C. RNA were extracted and separated by electrophoresis in formaldehyde-containing agarose gel. After transfer, the membrane was hybridized with a probe corresponding to KDR, Grb10 and 18S Figure 5 Expression of Grb10 increases KDR protein and its tyrosine phosphorylation. 293 cells were transfected with pcDNA-KDR-Myc without or with pcDNA3-Grb10-HA. After stimulation with VEGF (50 ng/ml for 10 min at 378C), proteins were separated by SDS ± PAGE and revealed by a Western blot with antibodies to phosphotyrosine, to Myc (9E10), to HA (12CA5) or to Shc Figure 6 The tyrosine kinase activity of KDR mediates its tyrosine phosphorylation after Grb10 expression. 293 cells were transfected with pcDNA3-KDR-Myc, or pcDNA3-KDR KD in absence or in presence of pcDNA3-Grb10-HA. Cells were stimulated with 50 ng/ml of VEGF for 10 minutes at 378C. Proteins were separated on SDS ± PAGE and revealed by a Western blot with antibodies to phosphotyrosine, to Myc, to HA or to Shc. Western blots were revealed on Storm 840 (Molecular Dynamics) 8 compared to lanes 5, 6). This result suggests that after Grb10 expression KDR basal tyrosine phosphorylation is due to autophosphorylation.
The increase in KDR proteins can be correlated with the activation of signaling pathways, such as MAP kinase. 293 cells were transfected with KDR in absence or in presence of Grb10, and MAP kinase activity was tested using a MBP (myelin basic protein) kinase assay (Figure 7) . VEGF increases the ability of MAP kinase to phosphorylate MBP. Expression of Grb10 increases both basal and VEGF-stimulated MAP kinase activity.
We were interested to see whether Grb10 expression would aect endogenous KDR in HUVEC cells. Human endothelial cells (HUVEC) were transfected with pcDNA3 vector (mock) or with a vector expressing Grb10-HA. Cells were stimulated with VEGF, and whole cell lysates were analysed by Western blotting with antibodies to phosphotyrosine, to KDR and to HA. VEGF induces tyrosine phosphorylation of endogenous VEGF receptors ( Figure 8 ). As we have observed in 293 cells ( Figure  5 ), expression of Grb10 in HUVEC increases both the basal and the VEGF-induced tyrosine phosphorylation of endogenous KDR, as well as the total amount of KDR.
Grb10 SH2 domain is not required for the increase in KDR amount and tyrosine phosphorylation
We have shown that the SH2 domain of Grb10 is required to allow Grb10 tyrosine phosphorylation by activated KDR. To determine whether the Grb10 SH2 domain is also required to promote the positive action of Grb10, we expressed KDR in presence of Grb10 wild-type, Grb10 R 462 K (SH2 domain de®cient mutant) or the BPS-SH2 region (Figure 9 ). Since the BPS region does not bind to KDR (Figure 1c) , we assume that the eect will be due only to the SH2 domain. 293 cells were stimulated with VEGF and cell extracts were analysed by an immunoblot using antibodies to phosphotyrosine, Myc or HA. As we have previously shown, expression of Grb10 induces an increase in phosphorylation (blot anti-phosphotyrosine) and the amount of KDR (blot anti-Myc) (lanes 3, 4 compared to lanes 1, 2). The same result is obtained after expression of Grb10 R 462 K (lanes 9, 10 compared to lanes 1, 2). By contrast, expression of the SH2 domain of Grb10 (Grb10 SH2) does not modify the KDR amount or tyrosine phosphorylation compared to KDR expressing cells (lanes 5, 6 compared to lanes 1, 2). In conclusion, the stimulatory action of Grb10 on KDR expression and phosphorylation does not require a functional SH2 domain.
Specificity of Grb10 action on KDR
We investigated whether the stimulatory action of Grb10 on KDR is speci®c. To do so, we studied another SH2 domain containing molecule, Grb2. 293 cells were transfected with KDR alone, or in combination with Grb10 or Grb2 (Figure 10a ). After VEGF treatment, cell extracts were analysed by Western blot using antibodies to phosphotyrosine, to Myc, to HA and to Grb2. As previously observed, Grb10 expression increases both the tyrosine phosphorylation and the amount of KDR. This appears to be speci®c since Grb2 does not mimic the eect of Grb10 on KDR. Expression of Shc, which contains a SH2 domain, has the same eect as Grb2, and did not modify the amount nor the phosphorylation of KDR (data not shown). Expression of Grb10 stimulates VEGF-induced MAP kinase activity. 293 were transfected with pcDNA-KDR-Myc and pcDNA3-Grb10-HA. Cells were stimulated with VEGF (50 ng/ml for 10 min at 378C), and MAP kinase was immunoprecipitated and tested for its ability to phosphorylate myelin basic protein Figure 8 Expression of Grb10 in HUVEC increases KDR expression and phosphorylation. HUVEC (passage 2) were transfected with pcDNA3 (Mock) or pcDNA3-Grb10-HA, and stimulated with VEGF (20 ng/ml for 5 min). Proteins were separated on SDS-PAGE and revealed by a blot with antibodies to phosphotyrosine, to KDR or to HA. Western blots were revealed on Storm840 Molecular Dynamics Figure 9 The SH2 domain of Grb10 is not implicated in the positive regulation of KDR. (a) 293 were transfected with pcDNA3-KDR-Myc, without or with pcDNA3-Grb10-HA, Grb10 R 462 K-HA or Grb10 SH2-HA. Cells were stimulated with 50 ng/ml of VEGF for 10 minutes at 378C. Proteins were separated on SDS ± PAGE and revealed by a Western blot with antibodies to phosphotyrosine, to Myc or to HA. (b) Quanti®cation of experiments Figure 10 Speci®city of Grb10 action. (a) 293 were transfected with pcDNA3-KDR-Myc, without or with pcDNA3-Grb10-HA or pcDNA3-Grb2. Cells were stimulated with 50 ng/ml VEGF for 10 min at 378C. Proteins were separated on SDS ± PAGE and revealed by a Western blot with antibodies to phosphotyrosine, to Myc, to HA and to Grb2. (b) 293 were transfected with pcDNA3-IR, without or with pcDNA3-Grb10-HA or pcDNA3-Grb2. Cells were stimulated with 100 nM insulin for 10 min at 378C. Proteins were separated on SDS ± PAGE and revealed by a Western blot with antibodies to phosphotyrosine, to insulin receptor, to HA and to Grb2
This stimulatory eect of Grb10 seems to be speci®c for KDR. Since Grb10 has been shown to interact with other tyrosine kinase receptors, such as the insulin receptor, we expressed the insulin receptor with Grb10 or Grb2 (Figure 10b ). We observed that insulin treatment of cells induces an increase in insulin receptor tyrosine phosphorylation, which is not changed when Grb10 or Grb2 are expressed in combination with the insulin receptor. The amount of insulin receptor was not modi®ed by the expression of Grb2 or Grb10.
Discussion
VEGF is one of the major factors involved in angiogenesis. This growth factor is acting through activation of its tyrosine kinase receptors Flt-1 and KDR, but the signaling pathways activated by these receptors are poorly identi®ed.
Here, we show that VEGF induces an increase in Grb10 mRNA level, and then stimulates tyrosine phosphorylation of endogenous Grb10 in HUVEC. This phosphorylation is dependent on the intact Grb10 SH2 domain, since mutation of the SH2 domain abolishes Grb10 tyrosine phosphorylation in response to VEGF. Until now, it was known that growth factors, such as EGF or insulin, do not stimulate tyrosine phosphorylation of Grb10, but rather induce its serine phosphorylation (Dong et al., 1997; Ooi et al., 1995) . Our results show for the ®rst time that a growth factor, VEGF, acting through activation of its tyrosine kinase receptor, is able to induce Grb10 tyrosine phosphorylation. Src is involved in VEGFmediated angiogenesis and has been shown to be required for VEGF-mediated PLCg activation (Eliceiri et al., 1999; He et al., 1999) . Moreover, Src phosphorylates Grb10 (Langlais et al., 2000) . Here, we have found that VEGF-induced tyrosine phosphorylation of Grb10 is partially due to Src. Indeed, treatment of cells with a Src inhibitor did not completely abolish the tyrosine phosphorylation of Grb10. These results suggest that Grb10 is a substrate for Src, but also a substrate for KDR. The latter would suggest that a direct interaction between KDR and Grb10 could occur. Indeed, in the yeast two hybrid system, we detected an interaction between Grb10 and KDR. However, we were unable to show coprecipitation between Grb10 and KDR either in HUVEC or in transfected cells (data not shown). This may be due to limitations inherent to the immunoprecipitation technique. Using the yeast two hybrid system, it has been shown that IRS-1 and Shc associate directly with the insulin receptor (Gustafson et al., 1995; TartareDeckert et al., 1995) , while it is impossible to coimmunoprecipitate these proteins. In yeast two hybrid system, we show that the interaction between Grb10 and KDR is dependent on the receptor tyrosine kinase activity and on the integrity of the SH2 domain of Grb10. Grb10 SH2 domain recognizes speci®c tyrosine phosphorylated sequences in several tyrosine kinase receptors (Frantz et al., 1997; Stein et al., 1996; Wang et al., 1999 (Dougher-Vermazen et al., 1994; Wu et al., 2000) . However, mutation of several KDR tyrosine residues, including autophosphorylation sites, did not allow us to identify the binding site of Grb10 on KDR (data not shown).
Interestingly, ectopic expression of Grb10 in 293 cells induces an increase in KDR molecules and in tyrosine phosphorylation. Importantly, the same observation is made in HUVEC. This eect is not mediated by the SH2 domain of Grb10 since expression of the mutant R 462 K leads to an increase in KDR molecules, and expression of the SH2 domain alone does not induce this increase. Since Grb10 R 462 K is not phosphorylated in response to VEGF, this suggests that the tyrosine phosphorylation of Grb10 is not required for the action of Grb10 on KDR. The increase in KDR expression can be correlated with an increase in MAP kinase activation. Moreover, this eect appears to occur speci®cally on KDR, since expression of Grb10 does not change the amount nor the tyrosine phosphorylation of insulin receptors. To the best of our knowledge, this is the ®rst demonstration of an action of Grb10 on regulation of the amount and phosphorylation state of a tyrosine kinase receptor.
To explain our results, we could hypothesize that expression of Grb10 would prevent receptor degradation leading to an increase in receptors at the cell surface, by a mechanism which remains to be identi®ed. A protein ubiquitin ligase NEDD4 associates with the SH2 domain of Grb10. However, it is unlikely that Grb10 prevents KDR degradation by recruiting NEDD4, since we have observed that the Grb10 SH2 domain is not required to mediate the increase in KDR molecules. Expression of Grb10 leads also to enhanced tyrosine phosphorylation of KDR in both basal and VEGF-stimulated conditions. The basal tyrosine phosphorylation of KDR is due to the tyrosine kinase activity of the receptor itself, since expression of a kinase-dead KDR abolishes the basal tyrosine phosphorylation of the receptor after Grb10 expression. We propose that the increased number of KDR molecules at the plasma membrane will lead to receptor dimerization, which induces receptor activation and autophosphorylation. Moreover, it is possible that the receptors will not be maintained in an inactivated state, due to a reduced activity of phosphotyrosine phosphatases which are in limited amount compared to the receptors.
Since VEGF stimulates Grb10 mRNA expression, it is tempting to propose that during neovascularisation, VEGF interacts with its receptors, and activates signaling pathways which lead to an increase in Grb10 proteins. Grb10 in turn would upregulate VEGF receptors.
Involvement of Grb10 in VEGF signaling pathway S Giorgetti-Peraldi
Taken together, our results suggest the existence of a positive feed-back loop in which VEGF induces increased Grb10 expression, and in which Grb10 increases the level of VEGF receptors. Under physiological conditions, this loop would provide a way to amplify the angiogenic action of VEGF.
Materials and methods
Materials
VEGF was purchased from Peprotech (Tebu, France). Antibodies to MAPK (06-182) and to phosphotyrosine (clone 4G10) were purchased from UBI (Lake Placid, NY, USA), and antibodies to Grb2 (sc-255), Grb10 (sc-1026), and insulin receptor (sc-711-G) were purchased from Santa Cruz (Santa Cruz, CA, USA). Antibodies to HA (clone 12CA5) were obtained from Roche Diagnostics (Meylan, France). Antibodies to Shc were obtained from BD Transduction Laboratories (Franklin Lakes, NJ, USA). Antibodies to KDR were obtained from Sigma (St. Louis, MO, USA). Insulin was a kind gift from Novo Nordisk (Copenhagen, Denmark).
Synthetic de®ned dropout yeast media lacking the appropriate amino acids were obtained from BIO101 (La Jolla, CA, USA). Oligonucleotides were purchased from Life Technologies (Gaithersburg, MD, USA), and enzymes were from New England Biolabs (Beverly, MA, USA). PP2 was purchased from Calbiochem (La Jolla, CA, USA), and all chemical reagents were from Sigma (St. Louis, MO, USA).
DNA plasmids
KDR cDNA was obtained from Masabami Shibuya (University of Tokyo, Japan). The cytoplasmic region of KDR (aa 790 ± 1357) was subcloned into pLexA vector. Fulllength KDR cDNA was subcloned in pcDNA3-MycA vector (Invitrogen, San Diego, CA, USA). Grb10 cDNA (nucleotide 1 ± 1612) was subcloned in pACTII vector. An epitope tag HA (YPYDVPDYAGPAAYPYDVPDYAGP) was added at the 3' end of the Grb10 cDNA, and was subcloned in pcDNA3 vector.
All KDR and Grb10 point mutants were generated by the Quickchange site-directed mutagenesis kit (Stratagene, San Diego, CA, USA). Sequences of the constructs were checked by sequence analysis.
Yeast strains, transformation and b-galactosidase assay
The yeast strain L40 (MAT a, trp1, leu2, his3, LYS2 ::lexAHis3, URA3 ::lexA-lacZ) were obtained from A Vojtek (Fred Hutchinson Cancer Research Center, Seattle, WA, USA). Plasmid DNA transformations were performed using the lithium acetate method. Cotransformants were selected on Trp-, Leu-plates. The transformants were tested for bgalactosidase activity by liquid culture assays using the chlorophenol red-b-D-galactopyranoside as described by Miller (1972) .
Cell culture
Human embryonic kidney cells, 293 EBNA, were maintained in culture in Dulbecco's modi®ed Eagle's medium (DMEM) containing 5% (vol/vol) fetal calf serum (Hyclone) and 500 mg/ml Geneticin.
Human Umbilical Vein Endothelial Cells (HUVEC) were isolated from umbilical cords by digestion with collagenase (Barbieri et al., 1981) , or were obtained from Clonetics (Walkersville, MD, USA). Cells were grown in EBM-2 supplemented with endothelial cell medium (Clonetics, Walkersville, MD, USA).
Transient transfection
Transfection of 293 EBNA were performed by calcium phosphate precipitation (10 mg of DNA/9.5 cm 2 dish). Sixteen hours after transfection, the calcium phosphate-DNA precipitates were removed, and cells were incubated in DMEM containing 5% fetal calf serum (v/v). Before use, cells were serum-starved for 16 h in DMEM containing 0.2% BSA (w/v).
Transfection of HUVEC were performed using Superfect kit according manufacturer's instructions (Qiagen, Courtaboeuf, France).
Immunoprecipitation and Western blot
Serum-starved cells were treated by ligands, chilled to 48C and washed with ice-cold PBS (140 mM NaCl, 3 mM KCl, 6 mM Na 2 HPO 4 , 1 mM KH 2 PO 4 , pH 7.4), and solubilized with lysis buer (50 mM HEPES, 150 mM NaCl, 10 mM EDTA, 10 mM Na 4 P 2 O 7 , 100 mM NaF, 2 mM Vanadate, 0.5 mM PMSF, 10 mg/ml aprotinin, 10 mg/ml leupeptin, pH 7.4, 1% Triton X-100) for 15 min at 48C. Cell homogenates were clari®ed by centrifugation at 15 0006g for 10 min at 48C. Cell lysates were incubated with antibodies and protein-G Sepharose. The pellets were washed twice with lysis buer. Proteins were separated by SDS ± PAGE and transferred by electroblotting to poly(vinylidene di¯uoride) membranes (Immobilon PVDF, Millipore, Bedford, MA, USA). The membranes were soaked ®rst in blocking buer (20 mM Tris, pH 7.4, 137 mM NaCl, 0.1 % Tween 20) containing 5% (w/v) bovine serum albumin, and second in blocking buer containing speci®c antibodies. After washes, proteins were detected using horseradish peroxidase-linked secondary antibodies and enhanced chemiluminescence (Amersham Pharmacia Biotech, Uppsala, Sweden). When indicated, Western blots were revealed by ECL plus on Storm 840, Molecular Dynamics (Amersham Pharmacia Biotech) and analysed by Image Quant software (Amersham Pharmacia Biotech).
MBP kinase assay
Cell lysates were subjected to immunoprecipitation using antibodies to MAP kinase. After immunoprecipitation, pellets were washed with lysis buer, and with HNTG (30 mM HEPES, 30 mM NaCl, 0.1% Triton X-100, 10% glycerol). MBP phosphorylation were performed for 20 min at room temperature in presence of 150 mg/ml of myelin basic protein (MBP), 10 mM MgAc, and [g-32 P]ATP (5 mM, 33 Ci/mmol). The phosphorylation was stopped by spotting an aliquot of the samples on phosphocellulose paper ®lters (Whatman P81, Clifton, NJ, USA). After washes in 1% orthophosphoric acid, radioactivity associated with the dried paper ®lters was determined by Cerenkov counting.
Northern blot analysis
Total RNA was isolated from 100 mm dishes using the Trizol reagent according to the manufacturer's instructions (Life Technologies, Inc., Gaithersburg, MD, USA). Ten mg of total RNA was denaturated in formamide and formaldehyde, and separated by electrophoresis in formaldehyde containing agarose gel. RNA were transferred to Hybond-N membranes (Amersham Pharmacia Biotech, Uppsala, Sweden). Probes were labeled with g-32 P-dCTP by random priming using the Rediprime kit (Amersham Pharmacia Biotech, Uppsala, Sweden) and puri®ed with the Probequant kit (Amersham Pharmacia Biotech). Hybridizations were performed at 428C in NorthernMax Hybridization buer (Ambion, Inc, Austin, TX, USA). Membranes were washed in 16SSC, 0.5% SDS and revealed on Storm 840, Molecular Dynamics (Amersham Pharmacia Biotech).
